XML 49 R31.htm IDEA: XBRL DOCUMENT

Derivative Warrant Liabilities (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Outstanding Warrants Liabilities

The remaining outstanding warrants and terms as of September 30, 2018 and December 31, 2017 after the split is as follows: (*)

Issuance date		Outstanding as of December 31, 2017				Outstanding as of September 30, 2018				Exercise Price				Exercisable as of September 30, 2018				Exercisable Through

Series A (2013)			3,895				3,895			$	2,885				3,895			October 2018
Series A (2013)			183				183			$	2,725				183			April 2023
Series A (2015)			683				683			$	1,363				683			April 2020
Series A (2016) (a)			625				-			$	-				-			March 2018
Series B (2016) (a)			2,770				2,770			$	40				2,770			March 2022

	(*)	December 31, 2017 warrants data represents the number of shares adjusted to retroactively reflect the 1:15 Reverse Split effected on September 4, 2018
	a)	These warrants contain a full ratchet anti-dilution price protection so that, in most situations upon the issuance of any common stock or securities convertible into common stock at a price below the then-existing exercise price of the outstanding warrants, the warrant exercise price will be reset to the lower common stock sales price. As such anti-dilution price protection does not meet the specific conditions for equity classification, the Company is required to classify the fair value of these warrants as a liability, with changes in fair value to be recorded as income (loss) due to change in fair value of warrant liability. The estimated fair value of our warrant liability at September 30, 2018 and December 31, 2017, was approximately $5 and $28, respectively.

The remaining outstanding warrants and terms as of December 31, 2017 and 2016 is as follows:

Issuance date		Outstanding as of *December 31, 2016()**				Outstanding as of *December 31, 2017()**				Exercise *Price ()**				Exercisable as of *December 31, 2017()**				Exercisable Through

Series A (2011)			4,327				-			$	2,244				-			December 2016
Series A (2013)			3,895				3,895			$	2,885				3,895			October 2018
Series A (2013)			183				183			$	2,725				183			April 2023
Series A (2015)			683				683			$	1,363				683			April 2020
Series A (2016)(a)			677				625			$	40				625			March 2018
Series B (2016)(a)			2,770				2,770			$	40				2,770			March 2022

	(*)	December 31 2017 and 2016 warrants data represents the number of shares adjusted to retroactively reflect the 1:15 Reverse Split effected on September 4, 2018.
	a)	These warrants contain a full ratchet anti-dilution price protection so that, in most situations upon the issuance of any common stock or securities convertible into common stock at a price below the then-existing exercise price of the outstanding warrants, the warrant exercise price will be reset to the lower common stock sales price. As such anti-dilution price protection does not meet the specific conditions for equity classification, the Company is required to classify the fair value of these warrants as a liability, with changes in fair value to be recorded as income (loss) due to change in fair value of warrant liability. The estimated fair value of our warrant liability at December 31, 2017 and December 31, 2016, was approximately $28 and $313, respectively.

Schedule of Valuation of Derivative Warrant Liabilities

The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of September 30, 2018 and December 31, 2017:

		Series A (2011)				Series A (2013)				Series A (2013)				Series A (2015)				Series A (2016)				Series B (2016)				Total
Balances at December 31, 2017		$	-			$	-			$	-			$	-			$	(*	)		$	28			$	28
Exercised			-				-				-				-				-				-				-
expiration			-				-				-				-				(*	)			-				(*	)
Changes in fair value			-				-				-				-				-				(23	)			(23	)
Balances at September 30, 2018		$	-			$	-			$	-			$	-			$	-			$	5			$	5

(*)

Less than 1

The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of December 31, 2017 and December 31, 2016 (in thousands)(**):

		Series A (2011)				Series A (2013)				Series A (2013)				Series A (2015)				Series A (2016)				Series B (2016)				Total
		(in thousands)
Balances at December 31, 2016		$	-			$	12			$	9			$	22			$	43			$	227			$	313
Exercised			-				-				-				-				-				-				-
Cancelled			-				-				-				-				-				-				-
Changes in fair value			-				(12	)			(9	)			(22	)			(43	)			(199	)			(285	)
Balances at December 31, 2017		$	-			$	-			$	-			$	-				$ (*)			$	28			$	28

	(*)	Less than 1
	(**)	Share data represents the number of shares adjusted to retroactively reflect the 1:15 Reverse Split effected on September 4, 2018.

Schedule of Fair Value Assumption

The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of September 30, 2018 and December 31, 2017:

		As of September 30, 2018								As of December 31, 2017
		Series A (2016)				Series B (2016)				Series A (2016)				Series B (2016)
Share price			—			$	7.52			$	15.1			$	15.1
Exercise price			—			$	40.07			$	40.07			$	40.07
Expected volatility			—				84.9%				60%				119%
Risk-free interest			—				2.39%				1.24%				1.89%
Dividend yield			—				—				—				—
Expected life of up to (years)			—				3.50				0.25				4.25

The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of December 31, 2017 and December 31, 2016:

		As of *December 31, 2017()**								As of *December 31, 2016()**
		Series A (2016)				Series B (2016)				Series A (2016)				Series B (2016)
Share price		$	15.1			$	15.1			$	90.5			$	90.5
Exercise price		$	40			$	40			$	40			$	40
Expected volatility			60	%			119	%			380	%			380	%
Risk-free interest			1.24	%			1.89	%			0.85	%			1.93	%
Dividend yield			—				—				—				—
Expected life of up to (years)			0.25				4.25				1.2				5.2

(*)

December 31 2017 and 2016 options data represents the number of shares adjusted to retroactively reflect the 1:15 Reverse Split effected on September 4, 2018.

Schedule of Liabilities Measured on a Recurring Basis

Activity in such liabilities measured on a recurring basis is as follows:

		Derivative Warrant Liabilities
As of December 31, 2017		$	28
Revaluation of warrants			(23)
As of September 30, 2018		$	5

		Derivative Warrant Liabilities
As of December 31, 2016		$	313
Revaluation of warrants			(285)
Exercise warrants			(*)
As of December 31, 2017		$	28

(*)

Less than 1

Activity in such liabilities measured on a recurring basis is as follows:

		Derivative warrant liabilities
		(in thousands)
As of December 31, 2016		$	313
Revaluation of warrants			(285	)
Exercise warrants			(*	)
As of December 31, 2017		$	28

(*) Less than 1

		Derivative warrant liabilities
		(in thousands)
As of November 30, 2016		$	575
Revaluation of warrants			(262	)
Exercise warrants			(*	)
As of December 31, 2016		$	313

(*) Less than 1

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details